大剂量倍他乐克治疗克山病的临床研究

打开文本图片集

【摘要】目的：研究分析克山病治疗采用大剂量倍他乐克的临床功效。方法：2022年1月—2023年4月，克山病患者就诊50例，随机数字表划分，常规组使用沙库巴曲缬沙坦予以患者治疗，观察组使用大剂量倍他乐克予以患者治疗，分析疗效。结果：心脏指标数据统计，观察组患者经由治疗后改善于两组间更为显著（P

【关键词】大剂量倍他乐克；克山病；临床功效

Clinical study on high-dose betaloc in the treatment of Keshan disease

ZHAO Guohua

People’s Hospital of Jingchuan County， Pingliang City， Gansu Province， Jingchuan， Gansu 744300， China

【Abstract】Objective： To study and analyze the clinical efficacy of high-dose betaloc in the treatment of Keshan disease. Methods： From January 2022 to April 2023， 50 patients with Keshan disease were treated with a random number table. The conventional group was treated with sacubarta and valsartan， while the observation group was treated with high-dose betaloc. The therapeutic effect was analyzed.Results： the data of Cardiac Index in the observation group were improved more significantly than those in the two groups after treatment （P

【Key Words】High-dose betaloc； Keshan disease； Clinical efficacy

克山病又称地方性心肌病，该病以心脏扩大，心律失常为主要表现，患病后，除损害心功能外，人体脑、肺、肾等均将受累，易诱发栓塞性疾病，因此克山病患者在患病期间并发症发病率较高，且具有一定病死率，对患者机体健康、生命安全存极大影响性[1]。（剩余3831字）